Stock Price
-$6.42
(-4.05%)
Stocks ranking below 40 in the combined assessment are generally not recommended for investment. With a less favorable outlook, these equities may carry higher risks and are not conducive to sound investment strategies. Caution is advised when considering such stocks.
Alphabet Inc.
$151.16 + $2.5 (1.68%)
Twilio Inc.
$58.95 + $1.68 (2.93%)
Snap Inc.
$58.95 + $1.68 (2.93%)
Source: gurufocus.com
May 27, 2026, 8:00 am
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines
Source: businesswire.com
May 27, 2026, 7:00 am
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare.
Source: globenewswire.com
May 19, 2026, 1:30 pm
OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Project in Labrador, aimed at defining the scope of copper-nickel sulphide mineralization traced over approximately 5 kilometres along the Main Zone. Previous drilling intersected mineralization at roughly 1-kilometre spacing, outlining the scale of the Main Zone discovery.
Source: fool.com
May 17, 2026, 2:32 pm
Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
Source: globenewswire.com
May 14, 2026, 11:43 am
OTTAWA, May 14, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is pleased to announce that it has entered into a binding subscription agreement with Pavilion Flow- Through L.P. (2026) 1 (the “Investor”) in respect of a non-brokered private placement (the “Private Placement”) of flow-through units of the Company (the “Units”) at a price of $0.52 per Unit for aggregate gross proceeds to the Company of $750,000.
Source: businesswire.com
May 6, 2026, 11:13 pm
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its upsized underwritten publ.
Source: seekingalpha.com
May 5, 2026, 5:31 pm
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript
Source: businesswire.com
May 5, 2026, 4:05 pm
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced that it has commenced underwritten public offerings of $150.0 million aggregate principal amount of convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and $100.0 million of shares of its common stoc.
Source: benzinga.com
May 5, 2026, 10:21 am
Viridian Therapeutics, Inc. (NASDAQ:VRDN) shares are up on Tuesday as the company announced positive topline results from its REVEAL-2 Phase 3 clinical trial for elegrobart, a treatment for chronic thyroid eye disease (TED).
Source: reuters.com
May 5, 2026, 7:05 am
Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic patients.
Source: businesswire.com
May 5, 2026, 7:01 am
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31, 2026. “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug's PDUFA target date. We delivered positive topline data fro.
Source: businesswire.com
May 5, 2026, 7:00 am
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disease (TED). Elegrobart is a subcutaneously delivered, half‑life‑extended monoclonal antibody targeting the insulin‑like growth factor‑1 rec.
Source: fool.com
April 21, 2026, 3:26 pm
Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.
Source: defenseworld.net
April 15, 2026, 2:19 am
Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,843,213 shares, an increase of 31.7% from the March 15th total of 8,233,141 shares. Approximately 10.8% of the shares of the stock are short sold. Based
Source: defenseworld.net
April 7, 2026, 1:25 am
Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) saw some unusual options trading activity on Monday. Traders acquired 7,501 put options on the company. This represents an increase of 3,294% compared to the typical daily volume of 221 put options. Wall Street Analyst Weigh In A number of research firms have recently weighed in on
Source: benzinga.com
April 6, 2026, 1:41 pm
The Phase 3 TEPEZZA OBI trial met its primary endpoint, showing a statistically significant 77% proptosis (bulging eyes) response rate among participants during the 24-week placebo-controlled period.
Source: barrons.com
April 6, 2026, 12:10 pm
Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is currently developing its own treatment for the disease.
Source: seekingalpha.com
April 2, 2026, 1:12 pm
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
Source: zacks.com
April 1, 2026, 9:10 am
Viridian Therapeutics (VRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Source: proactiveinvestors.com
March 30, 2026, 12:35 pm
Shares of Viridian Therapeutics (NASDAQ:VRDN) fell more than 30% Monday morning following the release of topline results from the company's REVEAL-1 trial in active thyroid eye disease (TED). The study, which tested the subcutaneous formulation of elegrobart, met its primary endpoint, signaling that the drug could gain approval.
